Status:
TERMINATED
Reducing Emergency Department Visits and Improving Glucose Control in Uncontrolled Type 2 Diabetes Using CGM Sensors at Hospital Discharge
Lead Sponsor:
Albert Einstein Healthcare Network
Conditions:
Type 2 Diabetes Mellitus
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Quality measures and cost-reduction methods are a high priority in the United States health care system. This includes the high burden of patients with uncontrolled Type 2 Diabetes. Innovative ways to...
Detailed Description
Rationale: Quality measures and cost-reduction methods are a high priority in the United States health care system currently. This includes the high burden of patients with uncontrolled Type 2 Diabete...
Eligibility Criteria
Inclusion
- inpatient uncontrolled Type 2 Diabetes patients defined by HbA1c of ≥9.0% within the last 2-3 months
- require an endocrinology consultation
- will be followed at AEMC endocrinology clinic
Exclusion
- patients with HbA1c \<9.0%
- patients not managed by AEMC endocrinology clinic
- Type 1 Diabetic patients
Key Trial Info
Start Date :
October 31 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2020
Estimated Enrollment :
58 Patients enrolled
Trial Details
Trial ID
NCT04277780
Start Date
October 31 2018
End Date
December 31 2020
Last Update
April 6 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Albert Einstein Medical Center
Philadelphia, Pennsylvania, United States, 19141